K6PC-5
Based on 4 publication(s) in Google Scholar
K6PC-5, a ceramide derivative, is a sphingosine kinase 1(SPHK1) activator and elicites a rapid transient increase in intracellular calcium levels. K6PC-5 has the potential for skin diseases involving abnormal keratinocyte, and neurodegeneration and virus infection research.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.27%
- CAS No.: 756875-51-1
- 화학식: C19H37NO4
- 분자량:343.50
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
Antiviral Compound Library
HY-L027
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) K6PC-5
More
Biological Activity
|
SphK1 |
EBOV |
K6PC-5 (1-10 μM; 24 h) increases the involucrin and loricrin levels in a dose-dependent manner in normal human epidermal keratinocytes (NHEKs). K6PC-5 promotes differentiation and proliferation of keratinocytes via intracellular Ca2+ signaling. In addition, K6PC-5 stimulates the phosphorylation of p42/44 extracellular signal-regulated kinase and c-Jun N-terminal kinase[1].
K6PC-5 (1-10 μM; 24 h) promotes fibroblasts proliferation and collagen synthesis in human fibroblasts. K6PC-5 induces intracellular Ca2+ concentration ([Ca2+]i) oscillations in human fibroblasts[2].
K6PC-5 (10, 25, and 50 μM; 48 h) significantly attenuates EBOV-induced infection in EBOV-infected EA.hy926 cells. K6PC-5 significantly reduces the virus titers in supernatants of infected cells and strikingly decreased the amount of VP40 in a concentration-dependent manner[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Normal human epidermal keratinocytes (NHEKs)
-
Concentration:1 μM, 5 μM, 10 μM
-
Incubation Time:24 h
-
Result:Increased the involucrin and loricrin levels in a dose-dependent manner.
-
Cell Line:Human fibroblasts
-
Concentration:1 μM, 5 μM, 10 μM
-
Incubation Time:24 h
-
Result:Promoted fibroblast proliferation and procollagen production in human fibroblasts significantly.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Intrinsically aged hairless mice (56 weeks old)[2]
-
Dosage:1% (vehicle (PEG:EtOH = 7:3))
-
Administration:Topical application; twice daily for 2 weeks
-
Result:Enhanced fibroblast proliferation, collagen production, and eventually increased dermal thickness.
Chemical Information
-
CAS No. 756875-51-1
-
Appearance Solid
-
분자량 343.50
-
화학식 C19H37NO4
-
Color White to off-white
-
SMILES
CCCCCCCC(C(C(NC(CO)CO)=O)CCCCCC)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Novel mechanism by which geniposide alleviates rheumatoid arthritis: Targeted inhibition of SphK1 negatively regulates S1P signaling, promotes HIF-1α acetylation-mediated degradation and blocks the VEGF-induced synovial angiogenesis. [Abstract]2025 Dec 23:150:157739. PMID: 41456528 -
Phytother Res
Geniposide Improves Glycolysis Driven Angiogenesis in Experimentary Arthritis by Inhibiting SphK1-PI3K-Akt-PFKFB3 Signal. [Abstract]2025 Aug;39(8):3419-3431. PMID: 40583637 -
Int Immunopharmacol
Liquiritigenin attenuates alcohol-induced liver inflammation by regulating the SphK1/S1P/SPNS2 signaling pathway. [Abstract]2026 Jan 1;168(Pt 2):115881. PMID: 41297343 -
Discov Oncol
Ritanserin suppresses acute myeloid leukemia by inhibiting DGKα to downregulate phospholipase D and the Jak-Stat/MAPK pathway. [Abstract]2023 Jul 1;14(1):118. PMID: 37392305
용액&용해도
DMSO : 100 mg/mL (291.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.28 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.28 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kwon YB, et al. Novel synthetic ceramide derivatives increase intracellular calcium levels and promote epidermal keratinocyte differentiation. J Lipid Res. 2007 Sep;48(9):1936-43. [Content Brief]
[2]. Jong-Kyung Youm, et al. K6PC-5, a sphingosine kinase activator, induces anti-aging effects in intrinsically aged skin through intracellular Ca2+ signaling. J Dermatol Sci. 2008 Aug;51(2):89-102. [Content Brief]
[3]. Imre G, et al. The sphingosine kinase 1 activator, K6PC-5, attenuates Ebola virus infection. iScience. 2021 Mar 5;24(4):102266. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9112 mL | 14.5560 mL | 29.1121 mL | 72.7802 mL |
| 5 mM | 0.5822 mL | 2.9112 mL | 5.8224 mL | 14.5560 mL | |
| 10 mM | 0.2911 mL | 1.4556 mL | 2.9112 mL | 7.2780 mL | |
| 15 mM | 0.1941 mL | 0.9704 mL | 1.9408 mL | 4.8520 mL | |
| 20 mM | 0.1456 mL | 0.7278 mL | 1.4556 mL | 3.6390 mL | |
| 25 mM | 0.1164 mL | 0.5822 mL | 1.1645 mL | 2.9112 mL | |
| 30 mM | 0.0970 mL | 0.4852 mL | 0.9704 mL | 2.4260 mL | |
| 40 mM | 0.0728 mL | 0.3639 mL | 0.7278 mL | 1.8195 mL | |
| 50 mM | 0.0582 mL | 0.2911 mL | 0.5822 mL | 1.4556 mL | |
| 60 mM | 0.0485 mL | 0.2426 mL | 0.4852 mL | 1.2130 mL | |
| 80 mM | 0.0364 mL | 0.1820 mL | 0.3639 mL | 0.9098 mL | |
| 100 mM | 0.0291 mL | 0.1456 mL | 0.2911 mL | 0.7278 mL |
K6PC-5 Related Classifications
HY-124042 Related Classifications
Powered by Bioz